What's in Huons Co., Ltd.'s pipeline?

Huons Co., Ltd. has 29 drugs in our index: 1 marketed, 0 filed, 15 in Phase 3, 2 in Phase 2, 11 in Phase 1.

Which companies overlap with Huons Co., Ltd.'s portfolio?

Top competitors by shared drug class: Galderma R&D, GlaxoSmithKline, Astellas Pharma Inc, Daewoong Pharmaceutical Co. LTD., Allergan.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/huons-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-09 · How we verify

Huons Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Huons Co., Ltd. pipeline: 1 marketed, 0 filed, 15 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 15 Phase 3 2 Phase 2 11 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Restasis	Restasis	marketed			Other
HU007	HU007	phase 3	GLP-1 receptor agonist	GLP-1R	Diabetes
HUC3-637	HUC3-637	phase 3
HU-014	HU-014	phase 3	Telomerase inhibitor	Telomerase	Oncology
Moisview Eye drop	Moisview Eye drop	phase 3	Ophthalmic lubricant / Dry eye disease therapeutic		Ophthalmology
Hutox Inj	Hutox Inj	phase 3	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)	Aesthetics, Neurology
HE 10	HE 10	phase 3
Hyalein Mini Eye Drops	Hyalein Mini Eye Drops	phase 3	Artificial tear / Lubricating eye drop	Ocular surface (cornea and conjunctiva)	Ophthalmology
Moisview	Moisview	phase 3			Other
HA 0.3%	HA 0.3%	phase 3	Hyaluronic acid derivative	Hyaluronic acid receptors (CD44, RHAMM)	Ophthalmology or Dermatology
High hyal Plus inj.	High hyal Plus inj.	phase 3	Hyaluronic acid derivative	Hyaluronic acid receptors (CD44, RHAMM)	Orthopedics / Dermatology
Humia inj.	Humia inj.	phase 3	Recombinant enzyme / Hyaluronidase	Hyaluronic acid (extracellular matrix component)	Oncology / General (adjuvant for drug delivery)

Therapeutic area mix

Other · 4
Ophthalmology · 3
Diabetes · 2
Aesthetics, Neurology · 1
Ophthalmology or Dermatology · 1
Orthopedics / Dermatology · 1
Oncology / General (adjuvant for drug delivery) · 1
Neurology, Dermatology, Aesthetics · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Galderma R&D · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Astellas Pharma Inc · 2 shared drug classes
Daewoong Pharmaceutical Co. LTD. · 2 shared drug classes
Allergan · 2 shared drug classes
AbbVie · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Qilu Pharmaceutical Co., Ltd. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Huons Co., Ltd.:

Cite this brief

Drug Landscape (2026). Huons Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/huons-co-ltd. Accessed 2026-06-09.